Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours by Fleischhack, G et al.
30 to 60% of patients with medulloblastoma and other malignant
brain tumours will relapse within 5 years of initial therapy, mostly
with a presentation as metastatic disease (Kuehl et al, 1998; Perek
et al, 1999). Due to the multimodality of the primary treatment,
therapeutic options in relapses are limited. There are few surgical
and radiotherapeutic options for local treatment. The number of
chemotherapeutic agents capable of passing the blood–brain
barrier after systemic administration or suitable for dose escalation
or for intrathecal administration is likewise limited. The ‘gold
standard’ drugs for intrathecal cytostatic therapy are methotrexate
and cytarabine. While both are highly effective in CNS
leukaemia/lymphoma, only methotrexate seems to be effective in
the treatment of malignant brain tumours (Blaney et al, 1991a,
1991b; Schmandt and Kuehl, 1998). Cytarabine alone has only
poorly documented activity in malignant brain tumours, and
methotrexate shows an augmented CNS toxicity after CNS irradi-
ation (Rubinstein et al, 1975; Blaney et al, 1991b). Other cytostatic
agents tested recently for intra-CSF (cerebrospinal fluid) adminis-
tration either show rapid clearance from the CSF (thiotepa and
ACNU), lack active metabolites (thiotepa) (Blasberg et al, 1975)
or have substantial toxicity (mafosfamide) (Slavc et al, 1998).
Agents studied in preclinical or clinical phase I/II trials are 
diaziquone (Berg et al, 1992), depot cytarabine (Chamberlain et al,
1993), topotecan (Blaney et al, 1995), temozolomide (Sampson 
et al, 1999), FdUrd (5-fluoro-2´-deoxyuridine) (Nakagawa et al,
1999) and monoclonal antiganglioside antibodies (Bergman 
et al, 1999). 
Experimental data on medulloblastoma cell lines as well as clin-
ical data on systemic administration of etoposide in patients with
neuroectodermal brain tumours reveal a significant cytotoxic
activity of etoposide in these tumours (Tomlinson et al, 1991;
Dunkel et al, 1998). However, after systemic intravenous or oral
administration the penetration of etoposide into the cerebrospinal
fluid is extremely poor (less than 3%), with high interindividual
variability (Kiya et al, 1992). While concentrations of 0.1 to 10 mg
ml–1 are cytotoxic in vitro, depending on cell line and exposure
time, the cytotoxic levels of etoposide in plasma and CSF are not
well known (Henwood and Brogden, 1990). 
In 1992 van der Gaast et al reported the successful intra-
CSF administration of etoposide in 2 patients with malignant
meningeosis resulting from small-cell lung carcinoma and
lymphoblastic leukaemia. Etoposide was administered intraven-
tricularly via an ommaya reservoir in 1 patient and intralumbarly
in the second patient. One was given in a dose of 0.5 mg etoposide
for 5 consecutive days. During a second course 3 weeks later the
same dose was applied 10 times every 12 hours. Both patients
showed no treatment-related side effects but a clear clinical and
cytological response. This was the first report of safe intraventri-
cular administration of low doses of etoposide in humans. 
Encouraged by these results we initiated a pilot trial to study the
feasibility of intraventricularly administered etoposide in children
and adolescents with relapsed metastatic brain tumours. 
PATIENTS AND METHODS 
Patient eligibility 
The study was designed as an open comparative multicentre investi-
gation that began in February 1998. The diagnosis of metastatic brain
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glioblastoma, ependymoma) was confirmed in all patients by histo-
logical examination of the primary tumour biopsy or of a tumour
biopsy at relapse by a reference neuropathologist according to the
WHO classification (Kleihues et al, 1993) and by typical MRI
(magnetic resonance imaging) findings. Patients aged above 1 year
with refractory or relapsed metastatic malignant brain tumours (i.e.
spinal, ventricular and/or parenchymatous metastases and/or
meningeosis) were eligible. Patients who were shunt-dependent or
displayed a proximal CSF flow obstruction or severe organ insuffi-
ciencies (e.g., renal, cardiac, pulmonary or hepatic), life-threatening
infections, severe neurologic lesions and/or therapy-resistant seizures
(WHO scale 4) were excluded (World Health Organisation, 1979). 
Study design 
The study was conducted in accordance with the updated declara-
tion of Helsinki and approved by the local ethics committee of the
University of Bonn. Prior to enrolment in the study, all patients
and their parents were informed of the investigational nature of the
study and the potential risks of this regimen as well as of the poor
prognosis of relapsed metastatic brain tumours, and their consent
to treatment was obtained. Patient data were collected consecu-
tively, recorded on data sheets prepared centrally beforehand,
checked by the principal investigator and deposited in a protected
database at the University of Bonn. 
Patient characteristics 
Between February 1998 and October 1999 14 patients were
enrolled in the trial from departments of paediatric
haematology/oncology in Germany. Patient baseline characteris-
tics at study entry are listed in Table 1. Current relapses were
documented both by symptoms and by the MRI in 8 patients, only
by MRI on routine examination in 6 patients, and additionally by
detection of tumour cells in the CSF of 5 patients. At study entry
disseminated disease was seen in all patients; 11 patients had
multifocal metastases, 5 additional local relapses, 3 meningeosis
and 10 spinal or ventricular metastases. 
At the time of initial diagnosis all patients were treated with
total (n = 11) or subtotal (n = 3) surgical excision of the primary
tumour. 12 patients received craniospinal irradiation and 11 were
treated with systemic multiagent chemotherapy according to
the German protocols HIT’88/89 (n = 2), HIT’91 (n = 8) or 
HIT-SKK’92 (n = 1) (Kuehl et al, 1993, 1998). At the time of
previous relapses 6 patients received systemic chemotherapy and 4
local irradiation. At the time of the current relapses prior to entry
into this study 5 patients underwent repeated surgery (2 sub-
total resections, 3 biopsies), one was treated with systemic
chemotherapy, and another underwent repeated irradiation.
Only 1 patient (no. 14) received intraventricular therapy with
methotrexate prior to this study. 
2 patients (10.2 and 32.5 years old) treated with continuous 
i.v. infusion of etoposide for a newly diagnosed disseminated 
medulloblastoma were not given etoposide intraventricularly and
served as a second experimental group for comparison of the
pharmacokinetic data. 
Chemotherapy 
Etoposide was used in the form of Vepesid® (Bristol-Myers Squibb,
Germany). A 5 ml vial contained 100 mg etoposide and, as solvents,
150 mg benzyl alcohol, 3250 mg macrogol 300, 1210 mg absolute
ethyl alcohol, citric acid and polysorbate 80. For intraventricular
administration via an indwelling Ommaya or Rickham reservoir
the commercial solution was diluted 200-fold with preservative-
free saline, yielding a final concentration of 0.1 mg ml–1. The final
solution was injected over a 2-minute period after draining of three
2 ml samples of CSF from the reservoir for discarding, for phar-
macokinetic analysis and for flushing the reservoir after the injec-
tion. 0.5 mg etoposide was administered daily via an Ommaya or
Rickham reservoir for 5 consecutive days. The courses were
repeated every 2 to 5 weeks (median = 4 weeks) over a period of 0
to 11 months (median = 3.5 months). A total of 59 courses were
administered. 
Concurrently or immediately after the intraventricular etoposide
therapy, all patients were treated with a course of systemic
chemotherapy consisting of continuous intravenous (CIV) infu-
sions of carboplatin and etoposide in conventional (800 mg m–2
and 400 mg m–2 respectively over 96 hours) or high doses (2000
mg m–2 and 1000 mg m–2 respectively over 96 hours), or orally
with etoposide and trofosfamide (25 mg m–2 and 100 mg m–2
respectively for 21 days) repeated every 4 to 5 weeks. Antiemetics
and analgesics were rarely necessary as supportive medication. 
Both patients of the second experimental group received a CIV
infusion of carboplatin and etoposide in a dose of 800 mg m–2 and
400 mg m–2 respectively over 96 hours and concurrently 8 times 
1 mg methotrexate every 12 hours intraventricularly via an
Ommaya reservoir. 
Analysis 
Toxicity and response 
Haematological and non-haematological toxicity was assessed in
all patients according to the WHO grading system (World Health
Organization, 1979). 
The tumour response was evaluated as the best overall response
and assessed by clinical symptoms, CSF cytology and MRI. The
radiographic response on MRI, i.e. the increase, decrease or
resolution of the leptomeningeal, ependymal or parenchymal
enhancement, and tumour size, were noted. Complete remission
(CR) was defined as complete disappearance of all tumour sites,
(ii) partial remission (PR) as a decrease of more than 50% in all
tumour sites, (iii) stable disease (SD) as less than 25% increase or
less than 50% decrease in tumour sites and no appearance of a
new tumour site, (iv) a mixed response (MR) as concurrence of
partial response in one or more tumour sites and progression of
another tumour site or manifestation of a new tumour, and 
(v) progressive disease (PD) as an increase of more than 25% in
one or more tumour sites and/or appearance of new tumours or
the onset of meningeosis. 
The duration of progression-free survival (PFS) was calculated
from initiation of the intraventricular therapy with etoposide to
documented progression or relapse, to death by any cause, or to
the last day of follow-up. 
Pharmacokinetic analysis 
Sampling 
In the main experimental group, CSF samples were taken daily
immediately before intraventricular etoposide administration
(trough levels, during 15 courses in 5 patients) and 15 minutes
after etoposide administration (peak levels, during 11 courses
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samples were collected 0.25, 1, 2, 4, 8, 12 and 24 hours after
etoposide injection. Blood samples were taken simultaneously 
2 hours (4 courses) or 4 hours (3 courses) after intraventricular
administration during courses without systemic etoposide
therapy. CSF levels of intralumbar etoposide were not recorded
because lumbar spinal metastases were present in 4 of 5 patients
studied. In 2 of these 4 patients a scintigraphic CSF flow study
was performed and showed partial obstruction in the lumbar
spinal canal but no obstruction in the more proximal regions. In
the other 3 patients, whose ventricular CSF samples were used for
calculation of pharmacokinetic parameters, an undisturbed CSF
flow was expected in view of the results of the pre-treatment
cerebral and spinal MRI. 
In the second experimental group, serial CSF samples for etopo-
side analysis were collected during 5 courses before infusion, at
the steady state of continuous infusion after 24, 48, 72 and 
96 hours, and 24 hours after the end of infusion. 
CSF and blood samples were collected in heparinized tubes
(heparin ammonium), rapidly centrifuged at 10 500 g for 
2 minutes within 20 minutes of collection, and frozen at –20˚C
pending analysis. 
Assay methodology 
Etoposide levels in the CSF were assayed by reversed-phase high-
performance liquid chromatography (HPLC) using two previously
described methods (Farina et al, 1981; Stremetzne et al, 1997). In
brief, a Hypersil® ODS RP-18 column (Knauer, Berlin, Germany)
was used as the stationary phase. The mobile phase consisted
of methanol/0.01 M Na2HPO4 (45:55 v/v) and was adjusted
with H3PO4 to pH 6.0. CSF samples (50 ml) were diluted with 
25 ml 0.02 M Na2HPO4 (pH 5.3) in order to prevent etoposide
degradation during chromatographic analysis. 
Plasma samples (100 ml) were mixed with 250 ml acetonitrile
for precipitation of plasma protein and centrifuged at 3200 g for 
10 minutes. The supernatant was evaporated to dryness and
the residue was dissolved in 100 ml of mobile phase. 40 ml of the
respective mixtures were injected onto the HPLC system. The
flow rate was set to 0.4 ml min–1 and etoposide was quantified for
CSF analysis by electrochemical detection and for plasma analysis
by UV detection (210 nm). At electrochemical detection the poten-
tials of the dual electrode cell were set to 100 mV and 500 mV
respectively. The limit of quantification of both methods was
0.01 mg ml–1. Accuracy and precision met the international criteria
for the validation of bioanalytical methods. 
Pharmacokinetics 
Pharmacokinetic data analysis was performed using the SIPHAR
Win software package (Simed, France). A 2-compartment model
was fitted to individual CSF concentration time profiles in order to
estimate pharmacokinetic parameters such as clearance (Cltot),
half-lives (t1/2 alpha, t1/2 beta), the volume of distribution at steady state
(Vss) and the area under the curve (AUC). 
Statistical analysis 
The data were analysed using descriptive statistics to evaluate pre-
treatment and post-treatment patient characteristics as well as
progression-free survival (PFS). The interindividual and intraindi-
vidual variability of the pharmacokinetic parameters was calcu-
lated on the basis of the mean and the standard deviation of each
patient. The Mann–Whitney U test was used for comparison of the
pharmacokinetic parameters in the different groups. In all statis-
tical tests values of P < 0.05 at alpha < 0.05 were considered
significant. Statistical calculations were performed with the SPSS
software package (Statistical Program for Social Science, version
9.0.1., Chicago, USA). 
RESULTS 
Toxicity 
All 59 courses of intraventricular etoposide were evaluable for
toxicity. Each patient received a median of 4 courses (range: 1 to
12 courses). Nonhaematological side effects were observed in the
form of mild transient headache in 2 courses and of infectious
complications as meningitis in 2 of 59 courses. Both were treated
successfully with analgesics and antibiotics respectively.
Secondary to a malfunction, one patient required reservoir revision
following the fourth course of intraventricular etoposide. One
patient developed recurrent headache and vomiting about 12 hours
after the first administration of intraventricular etoposide. Prior
to treatment he had craniospinal meningeosis documented
by MRI accompanied by a high ventricular CSF protein level
(1266 mg 1–1) and CSF cytology positive for tumour cells.
Therapy with steroids, antiemetics and analgesics was intensified
and a second intraventricular administration of etoposide was
performed 24 hours after the first application. About 4 hours after
the second administration the patient presented with headache,
vomiting, temporary confusion and transient coma. One day later
the patient had a generalized seizure associated with a hypona-
traemia resulting from increased intracranial pressure and inappro-
priate secretion of the antidiuretic hormone. At this time an MRI
scan showed rapid progression of disease with marked
meningeosis and a beginning brain oedema. After antiepileptic
therapy the seizure stopped immediately, and after diuretic and
steroid therapy the coma subsided within 24 hours. The patient
received no further chemotherapy and died from progressive
disease one month later. 
Apart from these transient side effects, no acute or chronic toxic
encephalopathy, no pleocytosis or aseptic meningitis, and no toxic
death were observed. There was no haematological toxicity
attributable to intraventricular etoposide. 
Response 
The effectiveness of the intraventricular therapy could not be
assessed independently in all patients because 13 patients received
systemic chemotherapy simultaneously and one underwent irradi-
ation immediately before the intraventricular etoposide (Table 1). 
Clinically, 5 patients showed a clear improvement in neuro-
logical symptoms or pain reduction, 6 showed no changes, and 3
had progressive symptoms. 
Immediately before treatment, CSF cytology was positive for
tumour cells in 5 patients, in 3 cases exclusively in the lumbar CSF
(once in 1 patient, twice in 2 patients) and in 2 cases in the ventricular
CSF (both twice). CSF cytology controlled by repeated ventricular
and lumbar CSF samples was evaluable in only 4 of these 5
patients (nos. 1, 4, 5 and 7). These 4 patients had clearance of their
CSF following 1, 2 and 5 courses of intraventricular etoposide
respectively. Negative CSF cytology was documented for the next
Intraventricular etoposide 1455
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 2 (nos. 4, 5 and 7) and 4 (no. 1) courses of intraventricular etopo-
side. Later, 2 of them (nos. 4 and 7) developed CSF dissemination
during systemic and intraventricular chemotherapy, while the
other 2 showed negative CSF cytology throughout the observation
time. 9 patients with initially negative CSF cytology remained
negative throughout the treatment period (1 to 11 months). 
With respect to the concurrent administration of intraventricular
and systemic chemotherapy, the best responses documented by
both MRI and CSF cytology were 2 CR, 7 PR, one SD, 2 MR and
2 PD following 1 to 4 months of study treatment. 
In 2 patients (nos 1 and 2) with spinal metastases, 111-Indium-
DTPA scintigraphy and somatostatin receptor scintigraphy
performed simultaneously with the MRI scan showed a reduction
in spinal CSF flow obstruction and a marked tumour regression. 6
of 10 patients with spinal or ventricular metastases at the time of
the current relapse showed initial regression (CR, PR) of these
metastases in the MRI scan. However, 2 of these 6 patients (nos 4
and 7) developed new parenchymatous cerebral tumour lesions
during the continued systemic and intraventricular therapy. 
Pharmacokinetic findings 
The pharmacokinetic analysis was performed during 11 courses of
intraventricular etoposide in 4 patients. Figure 1 shows the CSF
concentration time profile (mean, standard deviation) following
intraventricular etoposide administration on the first day of each
course for all analysed patients. The ventricular etoposide concen-
tration decreased in a similar biexponential fashion. The highest
concentrations were measured 0.25 hours after intraventricular
etoposide administration. Following administration, significant
cytotoxic levels of total etoposide above 1 mg ml–1 and 0.1 mg ml–1
were detected for 4 hours and 24 hours respectively (Table 2). 
In the group receiving no systemic etoposide therapy, plasma
levels of etoposide were not detectable 2 (4 courses) and 4 hours (3
courses) respectively after intraventricular etoposide administration. 
The pharmacokinetic data listed in Table 3 were determined
using a 2-compartment model for all courses. With the exception
of the volume of distribution (P = 0.042), no significant intergroup
differences were detected. Independent of concurrent systemic
etoposide therapy, the interindividual variability of the pharmaco-
kinetic parameters was more than 3 times higher than the intraindi-
vidual variability (i.e. AUC 67.9% vs. 13.8–19.4%, CI 81.1% vs.
15.9–19.8%, V ss 107.0% vs. 21.7–25.0%). 
To further analyse the impact of systemic intravenous etoposide
chemotherapy on the etoposide CSF concentration, the main study
group was compared with a second experimental group that did
not receive intraventricular etoposide but did receive a CIV eto-
poside infusion. Figure 2 shows the mean CSF peak and trough
concentrations in the main study group (15 courses, 5 patients)
following intraventricular etoposide administration on 5 consecu-
tive days and the mean CSF concentration in the second group
(5 courses, 2 patients) following a CIV etoposide infusion of
400 mg m–2 over 96 hours. Both CSF peak and trough levels were
clearly higher after the intraventricular therapy compared to the
intravenous etoposide infusion. The etoposide concentrations
achieved by systemic infusion were below 0.1 mg ml–1. 
DISCUSSION 
In patients with relapsed metastatic brain tumours, the multifocality
and the spread of tumour cells throughout the CSF require
chemotherapeutic regimens aimed at prolonging survival and
providing a possible cure. Besides the intensification of
chemotherapy by drug escalation in high-dose regimens, combina-
tion therapy consisting of systemic chemotherapy and intra-CSF
therapy might be a potentially useful approach to achieving cytotoxic
drug concentrations in tumour tissue, brain parenchyma and CSF.
Intraventricular etoposide 1457
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Figure 1 CSF concentration time profile following intraventricular etoposide
administration (0.5 mg) on the first day of a 5-day schedule (mean ± standard
deviation, in whole 11 courses in 4 patients, in part the number of
measurements is given above each data point) 
Table 2 CSF concentrations of etoposide following the first day of
intraventricular administration of 0.5 mg etoposide 
Time after administration Number of courses1 Etoposide concentration 
(hours) (n) (mean ± SD) 
(mg ml–1) 
0.25 9 9.03 ± 5.98 
1.00 10 4.49 ± 1.79 
2.00 11 3.03 ± 1.31 
4.00 9 1.31 ± 0.56 
8.00 8 0.42 ± 0.24 
12.00 9 0.30 ± 0.16 
24.00 10 0.11 ± 0.08 
1Etoposide levels were measured during 11 courses in four patients (nos. 1,
2, 3, 13). During 9 courses in 4 patients both levels at 0.25 and 24 hours
were obtained. SD = standard deviation. 
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Figure 2 CSF concentrations (mean ± standard deviation) following
intraventricular (IVC) etoposide administration (0.5 mg per day) on 5
consecutive days in the main study group (u; peak and trough levels, 15
courses in 5 patients) compared with CSF concentration following
continuous intravenous infusion (CIV, 400 mg m–2 over 96 hours) in the
second experimental group (s; trough and steady state levels, 5 courses in
2 patients) The systemic, i.e. intravenous or oral, chemotherapy should provide
an effective control of bulk disease and prevent systemic tumour
dissemination. The goals of intra-CSF therapy are to treat clinical and
subclinical leptomeningeal and pachymeningeal deposits and intra-
ventricular and intraspinal non-parenchymatous metastases as well
as floating tumour cells in the CSF and to prevent further seeding
into the leptomeninges (Grossman and Krabak, 1999). 
In this study, we report on the feasibility of intraventricular
administration of etoposide in heavily pretreated patients with
recurrent metastatic brain tumours who suffered a first to third
relapse. The efficacy of the intraventricular therapy alone could
not be assessed because all patients received additional systemic
chemotherapy concurrently or underwent repeated irradiation.
However, 6 out of 11 patients who had been previously treated
with regimens containing etoposide as short-term intravenous
infusions responded to the combined therapy in our study. This
fact and the response in patients with spinal and/or ventricular
metastases and/or with a positive CSF cytology suggest the
achievement of only suboptimal tumour cell drug concentrations
in their previous treatment (with the dose and schedule of etopo-
side used) rather than the existence of chemoresistance. However,
the observed mixed response in 2 patients, with the regression of
spinal metastases and the simultaneous development of new cere-
bral parenchymatous metastases, suggests insufficient drug pene-
tration into the parenchyma after the intraventricular and systemic
chemotherapy in these patients. The results of the animal study by
Savaraj et al (1992) support this assumption. Following intracis-
ternal etoposide administration in dogs, they detected high CSF
levels but tissue levels that fell exponentially with the distance
from the injection site. Thus, the response of parenchymatous
metastases or of local tumour recurrence cannot serve to evaluate
the effectiveness of intraventricular therapy with etoposide. It is
difficult to score response in these metastatic and heavily pretreat-
ed patients by other means because of difficulties in quantifying
accurately the tumour burden on the surface of the brain and of the
spinal cord, in the CSF and in the meninges. However, in a future
phase II trial of intraventricularly administered etoposide the
tumour response documented by (i) cerebral and spinal MRI scans
to evaluate meningeal and intracavitary metastases and 
(ii) cytology of the ventricular and lumbar CSF to evaluate
floating tumour cells should serve as a prospective end-point of
the study. 
In accordance with previous studies, the intraventricular adminis-
tration of etoposide at a dose of 0.5 mg on 5 consecutive days at a 2-
to 5-week interval is well tolerated and has low toxicity (Van der
Gaast et al, 1992; Slavc et al, 2000). The catheter-associated compli-
cation rate was similar to that reported by Chamberlain et al (1997) in
a larger cohort of 120 patients using Ommaya reservoirs and other
intraventricular catheter systems for intraventricular chemotherapy.
In our study the intraventricular administration of etoposide via an
Ommaya or Rickham reservoir proved to be easy and safe. 1 of the
14 study patients sustained a severe complication with a transient
coma following the second intraventricular etoposide administration.
Though etoposide toxicity could not be excluded, the documented
progression of disease was more likely to have been the cause of the
coma. Although we observed no acute or chronic neurological side
effects apart from transient mild headaches in any other patients, CSF
flow disturbances or CSF space obstructions might theoretically
result in extremely high levels of etoposide itself and of its solvents.
This might produce reversible or permanent damage to the brain
tissue, as was reported in an animal study of intracisternal etoposide
administration (Savaraj et al, 1992). To guarantee a rapid dilution of
etoposide and its solvents in the CSF and adequate distribution of the
drug in the subarachnoid space, as well as to prevent any leakage of
the drug into the epidural or subdural space, the intraventricular route
was chosen for etoposide administration. In addition, this route
makes administration easier and more tolerable for patients than the
intralumbar route. To evaluate the CSF flow before starting the intra-
CSF therapy, radionuclide ventriculography with 111-Indium-DTPA
is recommended in the future for all patients with suspected CSF
flow disturbances in the MRI (Chamberlain et al, 1999). 
Our pharmacokinetic analysis revealed significant cytotoxic
drug concentrations of etoposide in the CSF following intraven-
tricular administration, compared to low levels achieved by exclu-
sively continuous intravenous administration. In this study the
CSF levels in patients receiving etoposide only orally were not
determined. Taking into account that CSF etoposide levels did not
differ between patients with or without systemic oral etoposide
administration concurrently with the intraventricular application,
we assume that the CSF levels achieved after exclusively oral
etoposide administration are low. Etoposide is a lipophilic drug
that shows high plasma protein binding and therefore low penetra-
tion into the CSF. Assuming that an etoposide level of 0.1 mg ml–1
is the minimal cytotoxic level in the CSF (Henwood and Bragden,
1990), cytotoxic drug concentrations may be achieved only by
high-dose intravenous infusions (Hande et al, 1984; Postmus et al,
1984) or by intraventricular administration. The concentrations
achieved after intraventricular administration of 0.5 mg etoposide
exceed by 2- to 10-fold those resulting from high-dose intravenous
administration and may provide increased cytotoxic activity
against tumour cell deposits in the CSF space. However, cytotoxic
drug levels might be obtained by CIV infusions of etoposide or
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Table 3 Pharmacokinetic parameter in the CSF (mean ± SD) on the first day of intraventricular administration of etoposide 
(0.5 mg q 24 h, days 1–5) dependent on concurrent systemic chemotherapy with etoposide (25 mg m–2 per day, orally, days 1–21) 
Parameter Without systemic etoposide (n = 7) Concurrent systemic etoposide* (n = 4) All courses (n = 11) 
AUC (mg h ml–1) 21.90 ± 10.30 30.44 ± 5.04 25.01 ± 9.48 
t1/2 a (h) 1.15 ± 0.41 1.13 ± 0.21 1.14 ± 0.34 
t1/2 b (h) 7.65 ± 1.24 6.98 ± 1.06 7.41 ± 1.17 
Cltot (ml min–1) 0.56 ± 0.48 0.28 ± 0.05 0.46 ± 0.40 
Vss (l) 0.20 ± 0.18 0.08 ± 0.04 0.16 ± 0.15 
SD = standard deviation. *Oral etoposide was given 12 to 16 hours before intraventricular administration. oral etoposide, when the blood–CSF barrier is altered and more
permeable, i.e. by tumour cell infiltration of the brain or the
leptomeninges (Kiya et al, 1992; Relling et al, 1996). 
Our study is the first detailed report of pharmacokinetic parame-
ters of etoposide following intraventricular administration in
humans. After rapid distribution, the etoposide concentration in
the CSF declines in a biexponential pattern. Because of the low
protein concentration of ventricular CSF (< 50 mg dl–1), the
protein binding of etoposide in the CSF is low and this lipophilic
drug is rapidly cleared from the CSF, e.g. by CSF bulk flow.
Following an intraventricular administration of 0.5 mg etoposide
for 5 consecutive days, no drug accumulation was observed. The
high interindividual variability of the pharmacokinetic data (AUC,
clearance, volume of distribution) indicates that the CSF concen-
trations might be influenced by individual factors such as CSF
volume, CSF flow disturbances or obstructions, increased CSF
pressure, increased permeability of the CSF–brain barrier by
tumour cell infiltration, and cellular uptake and metabolism. 
Our preliminary data suggest that repeated intraventricular
etoposide administration is only minimally toxic and is well toler-
ated. It seems to have a cytotoxic effect on metastatic medulloblas-
toma and should be tested in phase II trials of this or other brain
tumours and neoplastic meningeosis. Further studies are needed to
identify patient characteristics affecting the CSF pharmacody-
namics and pharmacokinetics of etoposide, in order to optimize
the dose and schedule of its intraventricular administration. 
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